Last reviewed · How we verify

Tissueblue — Competitive Intelligence Brief

Tissueblue (BRILLIANT BLUE G) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Disclosing Agent [EPC]. Area: Ophthalmology.

marketed Disclosing Agent [EPC] P2X purinoceptor 7 Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

Tissueblue (BRILLIANT BLUE G) — Dutch Ophthalmic. Tissueblue works by binding to the P2X purinoceptor 7, a specific receptor on cells, to reveal or stain tissues.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Tissueblue TARGET BRILLIANT BLUE G Dutch Ophthalmic marketed Disclosing Agent [EPC] P2X purinoceptor 7 2019-01-01
Celtect OXATOMIDE marketed oxatomide P2X purinoceptor 7, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Disclosing Agent [EPC] class)

  1. Dutch Ophthalmic · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tissueblue — Competitive Intelligence Brief. https://druglandscape.com/ci/brilliant-blue-g. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: